Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
TNBC - Triple-Negative Breast CancerTriple Negative Breast CancerNSCLCNSCLC Stage IVNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNSCLC Stage IV Without EGFR/ALK Mutation
Interventions
RADIATION

Sterotactic Body Radiotherapy/SBRT

In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.

DRUG

Standard of care

Standard of care per physician discretion

Trial Locations (10)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11570

Memorial Sloan Kettering Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Commack, Commack

98109

Fred Hutchinson Cancer Research Center (Data Analysis Only), Seattle

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Unknown

Princess Margaret Hospital/Ontario Cancer Institute (Data Analysis Only), Toronto

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03808662 - Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung | Biotech Hunter | Biotech Hunter